Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy

Biomaterials

Volumn 39, Issue , 2015, Pages 131-144

  Li, Ke ^a   Liu, Hao ^a   Gao, Wei ^a   Chen, Mu ^a   Zeng, Yun ^a   Liu, Jiajun ^a   Xu, Liang ^b   Wu, Daocheng ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Apogossypolone; Chemotherapy; Combination therapy; Doxorubicin; Mulberry like dual drug complicated nanocarriers

Indexed keywords

CHEMOTHERAPY; EFFICIENCY; ELECTROSTATICS; ENCAPSULATION; FLUORESCENCE; HYALURONIC ACID; INFRARED DEVICES; LIGHT SCATTERING; MICELLES; NANOPARTICLES; ORGANIC ACIDS; PLANTS (BOTANY); SELF ASSEMBLY; STARCH; TRANSMISSION ELECTRON MICROSCOPY; TUMORS;

APOGOSSYPOLONE; COMBINATION THERAPY; DOXORUBICIN; DYNAMIC LIGHT SCATTERING METHOD; ELECTROSTATIC ABSORPTION; FLUORESCENCE SPECTROPHOTOMETER; NANO-CARRIERS; NEAR-INFRARED FLUORESCENCE IMAGING;

DRUG DOSAGE;

APOGOSSYPOLONE; APOGOSSYPOLONE AMPHIPHILIC STARCH; DOXORUBICIN; DOXORUBICIN HYALURONIC ACID NANOPARTICLE; GOSSYPOL DERIVATIVE; HYALURONIC ACID; MULBERRY LIKE DUAL DRUG COMPLICATED NANOCARRIER; NANOCARRIER; NANOPARTICLE; STARCH; UNCLASSIFIED DRUG; GOSSYPOL; MICELLE;

ABSORPTION; ACUTE TOXICITY; ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ELECTRON MICROSCOPE; ENCAPSULATION; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD 50; LIGHT SCATTERING; MALE; MICELLE; MORPHOLOGY; MOUSE; NONHUMAN; SPECTROFLUOROMETRY; SPECTROPHOTOMETER; STATIC ELECTRICITY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; HELA CELL LINE; MORUS; PROCEDURES;

MORUS (PLANT); MUS;

ANIMALS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GOSSYPOL; HELA CELLS; HUMANS; HYALURONIC ACID; MALE; MICE; MICE, INBRED BALB C; MICELLES; MORUS; NANOPARTICLES; STARCH;

EID: 84919472222     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.10.073     Document Type: Article

References (47)

1. Sun Y., Wu J., Aboukameel A., Banerjee S., Arnold A.A., Chen J., et al. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells invitro and invivo. Cancer Biol Ther 2008, 7:1420-1428.
2. Xin J., Zhan Y.H., Xia L.M., Zhu H.W., Nie Y.Z., Liang J.M., et al. ApoG2 as the most potent gossypol derivatives inhibits cell growth and induces apoptosis on gastric cancer cells. Biomed Pharmacother 2013, 67:88-95.
3. Zhan Y.H., Jia G.F., Wu D.C., Xu Y., Xu L. Design and synthesis of a gossypol derivative with improved antitumor activities. Arch Pharm 2009, 342:223-229.
4. Banerjee S., Choi M., Aboukameel A., Wang Z., Mohammad M., Chen J., et al. Preclinical studies of apogossypolone, a novel pan inhibitor of Bcl-2 and Mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas 2010, 39:323-331.
5. Zhang X.Q., Huang X.F., Hu X.B., Zhan Y.H., An Q.X., Yang S.M., et al. Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells invitro. Asian J Androl 2010, 12:697-708.
6. Niu X.G., Li S.B., Wei F., Huang J., Wu G., Xu L., et al. Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells invitro and invivo. Breast Cancer 2014, 21:223-230.
7. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8:741-752.
8. Yu H.L., Huang Q.R. Enhanced invitro anti-cancer activity of curcumin encapsulated in hydrophobically modified starch. Food Chem 2010, 119:669-674.
9. Ellis R.P., Cochrane M.P., Dale M.F.B., Duffus C.M., Lynn A., Morrison I.M., et al. Starch production and industrial use. JSci Food Agric 1998, 77:289-311.
10. Simi C.K., Abraham T.E. Hydrophobic grafted and cross-linked starch nanoparticles for drug delivery. Bioprocess Biosyst Eng 2007, 30:173-180.
11. Cole A.J., David A.E., Wang J., Galban C.J., Hill H.L., Yang V.C. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials 2011, 32:2183-2193.
12. Gao W., Sha B.Y., Zou W., Liang X., Meng X.Z., Xu H., et al. Cationic amylose-encapsulated bovine hemoglobin as a nanosized oxygen carrier. Biomaterials 2011, 32:9425-9433.
13. Kuo W.Y., Lai H.M. Changes of property and morphology of cationic corn starches. Carbohydr Polym 2007, 69:544-553.
14. Broxterman H.J., Georgopapadakou N.H. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. Drug Resist Updat 2005, 8:183-197.
15. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
16. Gee J.M.W., Howell A., Gullick W.J., Benz C.C., Sutherland R.L., Santen R.J., et al. Consensus statement. Endocr Relat Cancer 2005, 12:S1-S7.
17. Logman J.F.S., Heeg B.M.S., Botteman M.F., Kaura S., van Hout B.A. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol 2010, 21:1529-1536.
18. Lokich J.J., Zipoli T.E., Moore C., Sonneborn H., Paul S., Greene R. Doxorbicin vinblastine and doxorubicin cyclophospamide combination chemotherapy by continuous infusion. Cancer 1986, 58:1020-1023.
19. Ramalingam S.S., Dahlberg S.E., Langer C.J., Gray R., Belani C.P., Brahmer J.R., et al. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. JClin Oncol 2008, 26:60-65.
20. Tanabe M., Ito Y., Tokudome N., Sugihara T., Miura H., Takahashi S., et al. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer 2009, 16:301-306.
21. Deng Z.J., Morton S.W., Ben-Akiva E., Dreaden E.C., Shopsowitz K.E., Hammond P.T. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 2013, 7:9571-9584.
22. Zheng M.B., Yue C.X., Ma Y.F., Gong P., Zhao P.F., Zheng C.F., et al. Single-step assembly of DOX/ICG loaded lipid-polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano 2013, 7:2056-2067.
23. Mi J.X., Wang G.F., Wang H.B., Sun X.Q., Ni X.Y., Zhang X.W., et al. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma. Acta Pharmacol Sin 2008, 29:1467-1477.
24. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer invitro and invivo. ACS Nano 2013, 7:994-1005.
25. Chen Y., Bathula S.R., Li J., Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. JBiol Chem 2010, 285:22639-22650.
26. Greco F., Vicent M.J., Gee S., Jones A.T., Gee J., Nicholson R.I., et al. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-DOX-AGM in breast cancer cells. JControl Release 2007, 117:28-39.
27. Mondragon L., Orzaez M., Sanclimens G., Moure A., Arminan A., Sepulveda P., et al. Modulation of cellular apoptosis with apoptotic protease-activating factor 1 (Apaf-1) inhibitors. JMed Chem 2008, 51:521-529.
28. Vicent M.J., Greco F., Nicholson R.I., Paul A., Griffiths P.C., Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed 2005, 44:4061-4066.
29. Choi K.Y., Saravanakumar G., Park J.H., Park K. Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B 2012, 99:82-94.
30. Liu H., Li K., Lan L., Ma J., Zeng Y., Xu L., et al. Double-layered hyaluronic acid/stearic acid-modified polyethyleneimine nanoparticles encapsulating (-)-gossypol: a nanocarrier for chiral anticancer drugs. JMat Chem B 2014, 2:5238-5248.
31. Surace C., Arpicco S., Dufay-Wojcicki A., Marsaud V., Bouclier C., Clay D., et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol Pharmacol 2009, 6:1062-1073.
32. Besheer A., Hause G., Kressler J., Maeder K. Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. Biomacromolecules 2007, 8:359-367.
33. Lv S.X., Tang Z.H., Li M.Q., Lin J., Song W.T., Liu H.Y., et al. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 2014, 35:6118-6129.
34. Wang H., Zhao Y., Wu Y., Yl Hu, Nan K.H., Nie G.J., et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32:8281-8290.
35. Deng X.W., Cao M.J., Zhang J.K., Hu K.L., Yin Z.X., Zhou Z.X., et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of M1R-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 2014, 35:4333-4344.
36. Necas J., Bartosikova L., Brauner P., Kolar J. Hyaluronic acid (hyaluronan): a review. Vet Med 2008, 53:397-411.
37. Zhou B., Weigel J.A., Fauss L.A., Weigel P.H. Identification of the hyaluronan receptor for endocytosis (HARE). JBiol Chem 2000, 275:37733-37741.
38. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
39. Yan Y., Bjoernmalm M., Caruso F. Particle carriers for combating multidrug-resistant cancer. ACS Nano 2013, 7:9512-9517.
40. Gan Z.H., Zhang T., Liu Y.C., Wu D.C. Temperature-triggered enzyme immobilization and release based on cross-linked gelatin nanoparticles. Plos One 2012, 7. e47154.
41. Zhang H., Quan X., Chen S., Yu H.T., Ma N. "Mulberry-like" CdSe nanoclusters anchored on TiO2 nanotube arrays: a novel architecture with remarkable photoelectrochemical performance. Chem Mater 2009, 21:3090-3095.
42. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotech 2011, 6:815-823.
43. Zhang H., Wang G., Yang H. Drug delivery systems for differential release in combination therapy. Expert Opin Drug Deliv 2011, 8:171-190.
44. Shin H.C., Alani A.W.G., Rao D.A., Rockich N.C., Kwon G.S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. JControl Release 2009, 140:294-300.
45. Wu D.C., Wan M.X. Methylene diphosphonate-conjugated adriamycin liposomes: preparation, characteristics, and targeted therapy for osteosarcomas invitro and invivo. Biomed Microdevices 2012, 14:497-510.
46. Liao D., Liu Z., Wrasidlo W., Chen T.M., Luo Y.P., Xiang R., et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomed Nanotechnol Biol Med 2011, 7:665-673.
47. Tian Y.H., Li S.P., Song J., Ji T.J., Zhu M.T., Anderson G.J., et al. Adoxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35:2383-2390.